araag2/HINT huggingface dataset:
Clinical trial NCT01298505 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: pf-03654764 2.5mg plus fexofenadine 60mg, pf-03654764 5mg plus fexofenadine 60mg, placebo
SMILES: CC(C)CNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1, CC(C)CNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was stopped due to lack of evidence for clinical efficacy.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy subjects. (Healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination, including blood
             pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  A positive urine drug screen.

          -  Treatment with an investigational drug within 30 days (or as determined by the local
             requirement, whichever is longer) or 5 half-lives preceding the first dose of study
             medication.
Clinical trial NCT00726648 (phase 1/phase 2, status: completed)
Conditions: relapsing multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: cdp323, cdp323, cdp323, cdp323, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female and male subjects aged 18-65 years

          -  Relapsing form of MS with at least one clinical relapse in the 24 months before
             screening;

          -  Screening EDSS score of 0-6.5;

          -  Must be fully immunocompetent

          -  Female subjects of childbearing potential must agree to practice contraception methods

        Exclusion Criteria:

          -  Any conditions that could interfere with the contrast-enhanced MRI;

          -  Any clinically significant disease state or findings other than MS;

          -  Any clinically significant deviation from the pre-defined ranges for laboratory tests;

          -  Concomitant treatment with MS disease modifying drugs
Clinical trial NCT00707954 (phase 1/phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ta-7284, placebo of ta-7284
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically stable Type 2 Diabetes Mellitus

          -  Females without childbearing potential

          -  Body mass index (BMI) >= 18.5 kg/m2 and <= 39.9 kg/m2

          -  Hemoglobin A1c levels >= 6.5% and <= 10%

          -  Fasting blood glucose levels >= 140 mg/dL and <= 270 mg/dL

          -  Systolic blood pressure >= 95 mmHg and <= 160 mmHg, and diastolic blood pressure >= 50
             mmHg and <= 100 mmHg, and pulse rate >= 50 bpm

          -  Patients who have not been administered anti-diabetic medication within 2 weeks Prior
             to dosing

          -  Medicines if necessary for Hypertension or Dyslipidemia should be administered with
             stable dosage at least 3 months

          -  Treatment with diet and exercise should be unchanged for more than 3 months

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus or Secondary Diabetic Mellitus

          -  History of diabetic complications which need treatment

          -  Treatment with insulin, thiazolidinediones, thiazide diuretics、beta blockers or
             systemic steroids within 3 months prior to informed consent

          -  Serum creatinine > upper limit of the normal range

          -  Patients with significant complications
Clinical trial NCT01784757 (phase 1, status: active, not recruiting)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: odm-201 tablet a, odm-201 tablet b, odm-201 capsule formulation
SMILES: C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O, C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O, C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent (IC) obtained.

          -  Histologically confirmed adenocarcinoma of prostate

          -  Progressive metastatic disease

          -  Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone
             (LHRH) analogue or antagonist or bilateral orchiectomy

          -  Adequate bone marrow, hepatic and renal function

          -  Able to swallow the ODM-201 whole as a capsule or tablet.

        Exclusion Criteria:

          -  Previous chemotherapy for prostate cancer.

          -  Known metastases in the brain.

          -  History of other malignancy within the previous 5 years, except a basal cell carcinoma
             of skin.

          -  Known gastrointestinal condition that can significantly affect the absorption of the
             study treatment.
Clinical trial NCT00322608 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: npi-2358
SMILES: CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C2=CC=CC=C2)N=CN1
Eligibility criteria:

        Inclusion Criteria:

          -  ECOG performance status ≤ 2

          -  Pathologically or histologically confirmed solid tumor malignancy

          -  Patients must not be candidates for regimens known to provide clinical benefit.

          -  All adverse events of any prior chemotherapy, surgery, or radiotherapy, must have
             resolved to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) (v. 3.0) Grade ≤ 2, except for neurological toxicity that must have
             resolved to Grade ≤ 1.

          -  Adequate bone marrow reserve, hepatic and renal function

          -  Signed informed consent

        Exclusion Criteria:

          -  Administration of chemotherapy, biological, immunotherapy or investigational agent
             (therapeutic or diagnostic) within 21 days prior to receipt of study medication (6
             weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major
             surgery, other than diagnostic surgery, within 6 weeks before first study drug
             administration. Radiotherapy within 4 weeks (some types of radiation therapy are
             excluded regardless of interval since treatment).

          -  Significant cardiac history or findings

          -  Underlying conditions or medications associated with bleeding diathesis

          -  Disorders associated with significant vascular pathology

          -  Lung cancer with central chest tumors

          -  Prior treatment with vascular disruptive agents

          -  Seizure disorder requiring anticonvulsant therapy; prior transient ischemic attack or
             cerebrovascular accident

          -  Brain metastases

          -  Severe chronic obstructive pulmonary disease (COPD) with hypoxemia

          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy

          -  Known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C

          -  Patients with a prior hypersensitivity reaction to any product containing Solutol
             and/or propylene glycol

          -  Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically
             sterile or they must agree to use acceptable methods of birth control. Female patients
             with childbearing potential must have a negative serum pregnancy test. Male patients
             must be surgically sterile or agree to use an acceptable method of contraception.

          -  Concurrent, active second malignancy for which the patient is receiving therapy,
             excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
Clinical trial NCT01449487 (phase 1, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: ppc-5650, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Postmenopausal women or women who have undergone hysterectomy, and males between 18
             and 70 years of age

          -  Pain intensity during pain attack should be >5 on the GSRS questionnaire

          -  Hypersensitivity within the last 2 years measured with the barostat

          -  Patients able to co-operate and tolerate the experimental procedures (as assessed in
             the training visit)

          -  Patients on stable medication

          -  Only patients that do not take over the counter medication 24h before the two study
             sessions

        Exclusion Criteria:

          -  Any history of, or current condition or medication that, as judged by the
             investigator, may affect gastrointestinal function and the interpretation of the
             clinical data

          -  Any clinically relevant abnormal values from the laboratory tests on hematology,
             clinical chemistry, urine analyses and/or faeces testing, as judged by the
             investigator.

          -  Chronic extraintestinal pain dominating the clinical history

          -  Any known biochemical or structural abnormality of the digestive tract such as gluten
             enteropathy, bile acid diarrhea, lymphocytic colitis and/or collagenous colitis,
             Chronic inflammatory bowel diseases, chronic pancreatitis

          -  Major intra-abdominal surgery; appendectomy and minor laparoscopic gynecological
             surgery acceptable.

          -  Any planned surgical intervention within the duration of the trial.

          -  Any abdominal surgery

          -  Participation in any other clinical trial within three months prior to the
             pre-screening visit.

          -  Alcohol or drug abuse.
Clinical trial NCT01711853 (phase 1, status: completed)
Conditions: renal insufficiency, chronic
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: dabigatran etexilate
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Male and female patients aged 18 years and older

          2. Impaired renal function defined as a stable Cockcroft-Gault and/or actual creatinine
             clearance between 15-30 ml/min over the last 3 months before study participation.

          3. The single use of either aspirin or Vitamin K Antagonists

          4. Provision of informed consent.

        Exclusion criteria:

          1. Unstable renal function and Creatinin Clearance <15mL/min

          2. Patients treated with two or more platelet aggregation inhibitors

          3. Use of or indication for therapeutic heparin

          4. Patients with prosthetic heart valves

          5. Haemorrhagic disorder or bleeding diathesis

          6. Platelet count <100 109/L) at screening or during the last 30 days before screening.

          7. Participation in another drug trial in the last 30 days before screening.
Clinical trial NCT00265408 (phase 1, status: withdrawn)
Conditions: ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: aspirin, warfarin
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical and imaging diagnosis of cervicocephalic arterial dissection within 3 months.

        Exclusion Criteria:

          -  Any contraindication to aspirin or warfarin.
Clinical trial NCT00424775 (phase 1, status: terminated)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: mk0683, vorinostat
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Chemotherapy-naive patients who are histologically or cytologically diagnosed NSCLC
             with stage IIIB (not applicable of radical thoracic radiation) or stage IV

          -  Patients with normal organ function and bone marrow function

        Exclusion Criteria:

          -  Given radical thoracic radiation for NSCLC or radiation for other than original lesion
             within 3 weeks

          -  Any peripheral neuropathy above grade 2

          -  Any ascites, pleural effusion or pericardiac effusion which requires treatment

          -  Any uncontrolled concomitant illness

          -  Pregnant or breast-feeding
Clinical trial NCT01336244 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: glpg0778, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  healthy male, age 18-50 years

          -  body mass index (BMI) between 18-30 kg/m², inclusive.

        Exclusion Criteria:

          -  significantly abnormal platelet function or coagulopathy

          -  smoking

          -  drug or alcohol abuse

          -  hypersensitivity to any of the test substances
Clinical trial NCT00701298 (phase 1, status: terminated)
Conditions: unspecified adult solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy-proven solid tumor

               -  Metastatic or unresectable disease

          -  Tumor amenable to biopsy

          -  No curative or more effective treatment for this disease exists, in the opinion of the
             investigator

          -  Measurable disease by scans as assessed by RECIST criteria

          -  No untreated brain metastasis

               -  No longer receiving steroid therapy for previously treated brain metastasis

          -  Zubrod performance status of 0-2

          -  Bilirubin ≤ 1.5 times upper limit normal (ULN)

          -  SGOT or SGPT ≤ 2.5 times ULN (≤ 5 ULN if hepatic metastases present)

          -  Serum creatinine ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 50 mL/min

          -  ANC > 1,500/μL

          -  Platelet count > 100,000/μL

          -  Hemoglobin > 9 g/dL (transfusion allowed)

          -  No NYHA class III-IV cardiac problems (e.g., congestive heart failure or myocardial
             infarction within the past 2 months)

          -  No severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes,
             uncontrolled chronic renal or liver disease, or active uncontrolled infection [e.g.,
             HIV])

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after completion of study therapy

          -  Willing to undergo biopsies

          -  No medical or psychological conditions that, in the opinion of the investigator, may
             preclude the patient's ability to tolerate or complete the treatment, or to grant
             reliable informed consent

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, adequately treated stage I, II, or III cancer
             from which the patient is currently in complete remission, or any other cancer from
             which the patient has been disease-free for 5 years

          -  No prior extensive pelvic irradiation or prolonged nucleoside analogue pretreatment

          -  At least 28 days since prior and no concurrent chemotherapy, radiotherapy, surgery,
             biological therapy, anticancer agent, or other investigational drug
Clinical trial NCT00325572 (phase 1, status: terminated)
Conditions: autism, pervasive developmental disorder
ICD codes: Z13.41
Drugs: oral zinc and vitamin c supplements
SMILES: [Zn]
Reason stopped: 
    lack of efficacy to proceed to phase 2
  
Eligibility criteria:

        Inclusion Criteria:

          -  Ages 3-8 years

          -  Diagnosis of autism spectrum disorder

          -  Serum copper/zinc ratio greater than 2.0 or as determined in phase 1 of the study

        Exclusion Criteria:

          -  Known chromosomal disorder or neurological disorders other than autism
Clinical trial NCT00635804 (phase 1, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: mk-3281, placebo to mk-3281
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is judged to be in good/stable health based on medical history, physical
             examination, vital signs, and laboratory safety tests performed at the prestudy
             (screening) visit and/or prior to administration of the initial dose of study drug

          -  Participant has no clinically significant abnormality on electrocardiogram (ECG)
             performed at the prestudy (screening) visit and/or prior to administration of the
             initial dose of study drug

          -  Participants with female partner(s) of childbearing potential must agree to use a
             medically acceptable method of contraception during the study and for 90 days after
             the last dose of study drug

          -  Participant has a clinical diagnosis of chronic HCV infection (for Part II only).

        Exclusion Criteria:

          -  Participant has a history of stroke, chronic seizures, or major neurological disorder

          -  Participant has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular, hematological, immunological, renal, respiratory, or genitourinary
             abnormalities or diseases

          -  Participant has a history of neoplastic disease (including leukemia, lymphoma,
             malignant melanoma), or myeloproliferative disease, regardless of the time since
             treatment

          -  Participant has positive Hepatitis B surface antigen (or other evidence of active
             Hepatitis B infection) at the prescreening (study) visit

          -  For Healthy Panel (Part I), participant has evidence of chronic Hepatitis C virus
             infection at the prescreening (study) visit

          -  Participant has a history of documented Human Immunodeficiency Virus (HIV) infection
Clinical trial NCT00724971 (phase 1, status: completed)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: inotuzumab ozogamicin (cmc-544), rituximab (rituxan)
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  CD20 and CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.

          -  Prior therapy must have contained at least one dose of Rituximab therapy. Patients can
             not be refractory to Rituximab (refractory = PD under treatment or within 6 month

          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.

          -  Patients must not have received previous radioimmunotherapy.

          -  Patients tolerant to Rituximab.

          -  Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth
             factors (except erythropoietin), or investigational agents within 28 days before first
             dose of test article.

        Exclusion Criteria:

          -  Candidate for potentially curative therapies

          -  Subjects must not have received previous radioimmunotherapy.

          -  Subjects with autologous hematopoietic stem cell transplant within the last 6 months
Clinical trial NCT01607554 (phase 1/phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: irinotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    inadequate enrollment (2 subjects in 4 years)
  
Eligibility criteria:

        Inclusion Criteria:

        -INCLUSION:

        18 years of age or older Have received prior chemotherapy for histologically proven
        advanced non-small cell lung cancer, up to 3 prior treatments Tumors display high ISG15
        (ISG15H) at screening Life expectancy of at least 12 weeks ECOG/Zubrod performance status
        of 0-2 Provide informed consent permission to participate

        Adequate bone marrow function as follows:

        1. Absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2)
        Platelet count greater than or equal to 100,000/mm3 and 3) Absence of a regular red blood
        cell transfusion requirement

        Adequate hepatic function with:

          1. Total bilirubin less than or equal to 4.0 mg/dl, and

          2. SGOT or SGPT less than or equal to four times ULN

        Adequate renal function as defined by:

        1) Serum creatinine less than or equal to 1.5 x ULN

        Exclusion Criteria:

        Symptomatic brain metastases

        Pregnant women or nursing mothers

        Patients of child bearing potential must use adequate contraception.

        May not be receiving other concurrent chemotherapy or radiation therapy

        Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or
        active infections

        Previous hypersensitivity reaction to camptothecins
Clinical trial NCT01214616 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: afatinib 20mg, afatinib 40mg, vinorelbine iv 25 or 20mg/m2
SMILES: CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1, CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion criteria:

          -  Histologically confirmed diagnosis of malignancy that is advanced and for which
             standard therapies do not exist or are no longer effective.

          -  Life expectancy at least 12 weeks

          -  Eastern Cooperative Oncology Group Performance Status 0 or 1

          -  Adequate hepatic, renal, haematologic and other organ function

          -  Written informed consent

        Exclusion criteria:

          -  Chemotherapy, immunotherapy, surgery and radiotherapy within the past 4 weeks

          -  Prior treatment with afatinib and or vinorelbine

          -  Clinically significant active infectious disease